The transcription factor E2F is regulated during the cell cycle through interactions with the product of the retinoblastoma susceptibility gene and related proteins. It is thought that E2F-mediated gene regulation at the G1/S boundary and during S phase may be one of the ratelimiting steps in cell proliferation. It was reported that in vivo overexpression of E2F-1 in fihroblasts induces S phase entry and leads to apoptosis. This observation suggests that E2F plays a role in both cell cycle regulation and apoptosis. To further understand the role of E2F in cell cycle progression, cell death, and tumor development, we have blocked endogenous E2F activity in HBL-100 cells, derived from nonmalignant human breast epithelium, using dominantnegative mutants under the control of a tetracycline-dependent expression system. We have shown here that induction of dominant-negative mutants led to strong downregulation of transiently transfected E2F-dependent chloramphenicol acetyl transferase reporter constructs and of endogenous c-myc, which has been described as a target gene of the transcription factor E2F/ DP. In addition, we have shown that blocking of E2F could et~iciendy protect from apoptosis induced by serum starvation within a period of 10 d, whereas control cells started to die after 24 h. Surprisingly, blocking of E2F did not alter the rate of proliferation or of DNA synthesis of these cells; this finding indicates that ceil-cycle progression could be driven in an E2F-independent manner. In addition, we have been able to show that blocking of endogenous E2F in HBL-100 cells led to rapid induction of tumor growth in severe combined immunodeficiency mice. No tumor growth could be observed in mice that received mock-transfected clones or tetracycline to block expression of the E2F mutant constructs in vivo. Thus, it appears that E2F has a potential tumor-suppressive function under ce~ain circumstances. Furthermore, we provide evidence that dysregulation of apoptosis may be an important step in tumorigenesis.
A
Poptosis and cell cycle are closely hnked and tightly regulated processes that control tissue development, differentiation, and homeostasis (1) . It is well established that deregulated expression and altered function of the genes involved in cell cycle regulation contribute to the pathogenesis of cancer (2) . In the past few years, evidence accumulated that resistance toward apoptosis is another important factor for tumor development (3). This has originally been shown in the case of B cell malignancies (3) (4) (5) . One important regulator ofapoptosis is the bd-2 oncogene, which was identified at t(14; 18) chromosomal translocation breakThe first two authors contributed equally to this work. points in the majority of follicular B cell lymphomas. These translocations lead to juxtaposition of the bd-2 gene on chromosome 18, with the Ig heavy chain gene on chromosome 14. Subsequent overexpression of the bd-2 gene renders the lymphoma cells resistant to apoptosis. Thus dysregulation of apoptosis may be a causative event in the evolution of B cell malignancies.
The tumor suppressor gene p53 exerts its tumor-suppressing function by regulating both cell cycle and apoptosis. Induction ofapoptosis by p53 is at least in part due to its ability to regulate transcription of members of the bcl-2 gene family (6--8) . Recently, we have shown that the death-promoting gene bax, another member of the bd-2 gene family, is strongly downregulated in breast cancer tissue (9) . Thus, dysregulation of apoptosis might be not only an important step in the development of lymphoma but also in the development of solid tumors.
Apoptosis may sustain tissue homeostasis by balancing the effects of proliferation. The regulatory coupling of proliferation and apoptosis is suggested by several recent findings. A line of investigation relevant to this hypothesis has focused on features shared by the pathways ofapoptosis and proliferation. These studies have revealed that entry into S phase, an initial step in cell cycle progression, may also occur in the pathway of cell death (10) . One such study of prostate epithelial cells showed that apoptosis induced by testosterone withdrawal is preceded by reentry into the cell cycle: after receiving a stimulus that induces apoptosis, quiescent prostate epithelial ceils enter S phase and then die without completing the ceil cycle. A second line of investigation has focused on regulatory genes that control both proliferation and apoptosis. Expression of genes important for cell cycle regulation, including cydin D, c-myc, Rb, and p53, is associated not only with proliferation, but also with cell death (6, (11) (12) (13) . E2F-1, the first member of the family of E2F transcription factors, is thought to play a critical role in G1/S progression of the cell cycle (14) (15) (16) . E2F usually appears to function to control the transcription of a group of genes that encode proteins important for cell cycle progression during S phase; these proteins include dihydrofolate reductase, thymidine kinase, and DNA polymerase ot (14) . Transcriptional activities of E2F are modulated during the ceil cycle, mainly by the formation of complexes between E2F and several key regulators of cell cycle such as the retinoblastoma protein and related proteins (17) (18) (19) (20) (21) (22) . E2F-1 can form a heterodimer with another E2F-like protien DP-1 and have a synergistic effect on its transcriptional activity (23, 24) . Recently, it has been shown that artificial overexpression of exogenous E2F-1 in fibroblasts promotes S phase entry and subsequently leads to apoptosis (25) (26) (27) (28) .
It was the aim of this study to examine the role of E2F/ DP1 in apoptosis and cell cycle regulation. Using the tetracycline-dependent expression system, we established ceil lines containing inducible dominant-negative DP-1 or E2F-2 mutants. Our major findings are that (1) downregulation of endogenous E2F/DP activity does not affect the proliferation rate in the breast epithelial cell line HBL-100 but (2) leads to downregulation ofc-myc expression, (3) enhanced resistance to apoptosis, and (4) induction of tumorigenic growth in severe combined immunodeficiency (SCID) 1 mice.
Materials and Methods
Cells and Culture Conditions. HBL-100 cells were originally isolated from breast milk of an apparently healthy woman (9) . Cells were maintained in RPMI 1640 (Seromed-Biochrom, Hamburg, 1Abbreviations used in this paper: CAT, chloramphenicol acetyl transferase; EMSA, electrophoretic mobility shift assay; GTC, guanidium isothiocyanate; RT, reverse transcription; SCID, severe combined immunodeficiency. Germany), 10% heat-inactivated FCS, 2 mM L-glutamine (GIBCO, Karlsruhe, Germany) and penicillin--streptomycin (Seromed-Biochrom, Hamburg, Germany).
Preparation of mRNA and Reverse Transcription-PCR (RT-PCR).
RNA preparation was performed using the guanidium isothiocyanate (GTC)/CsC1 method. Briefly, cells or tissue were lysed with GTC solution (4 M GTC, 20 mM sodium acetate, pH 5.2, 0.1 mM dithiothreitol, 0.5% Sarcosyl (Sigma Chemical Co., Griinwald, Germany). The resulting GTC-cell lysate was layered on top of a CsC1 cushion (5.7 M, 100 mM EDTA). After ultracentrifugation at 150,000 g for 23 h at 18~ the RNA pellet was resuspended in Tris-EDTA (Tris, 10 re_M; EDTA, 5 raM, pH 7.4) and precipitated by 3 M sodium acetate and ethanol at -80~ for 30 man. Total RNA was extracted from cells and tissues as described above. Purification ofpoly(A +) RNA from 10 btg of total RNA was performed using the Dynabead mRNA purification kit (Dynal, Oslo, Norway). Detection of mRNA by PCR was performed as described, using a Geneamp RNA PCR kit (PerkinElmer Cetus, Uberlingen, Germany) and a thermocycler (Bachhofer, Reutlingen, Germany), according to the PCR protocol. DP-1, ADP-1, and AE2F-2 PCR products were sequenced and subsequently cloned into pUHD-3 and pKEX expression plasmids (see below). The following primers were used for amplification: ADP-I: 5' primer, 5'-CCGGAATTCCGGATGGCAAAA-GATGCCGGT-3'; 3' primer, 5'-CGCGGATCCGCGCTATTA-CAGGTTCTTGAAGGCAAT-3'; AE2F-2: 5' primer, 5'-CCG-GAATTCCGGATGCTGCAAGGGCCCCGG-3'; 3' primer, 5'-CGCGGATCCGCGCTATTACAGAGAGCAGCTCTG-GAT-3'; DP-I:
To analyze inducible AE2F-2, ADP-1, or DP-1 expression, RT-PCR was performed using an upstream primer from the 5' transcribed region of the expression plasmid pUHD-3 (5'-CAG-ATCGCCTGGAGACGCC-3'; this procedure resulted in fragment lengths of 784, 790, and 1,315 bp, respectively). [3-actin was amplified using the following primers: upstream, 5'-GAGCTG-CGTGTGGCTCCCGAGG-3'; downstream, 5'-CGCAGG-ATGGCATGGGGGAGGGCATACCCC-3' (resulting fragment length, 246 bp).
Stable Cell Line HBL-IO0 Expressing Inducible ADp-1 or AE2F-2. In the first step, the plasmid pUHD 15-1 (29) containing the tetracycline repressor gene (tet) fused with the viral VP16 coding region was linearized with ScaI, cotransfected with the resistance plasmAd pUC18 (puromycin resistance; Boehringer Mannheim, Mannheim, Germany), and selected for stable HBL-100 cell lines.
Truncated ADp-1 or AE2F-2 c-DNA contained the DNA binding and dimerization domain of DP-1 (1-235 aa) or E2F-2 (1-233 aa) but were devoid of the NH2-terminal transactivation domain (23, 30--32) . Constructs were derived from RT-PCR, sequenced, and cloned into the expression plasmid pUHD 10-3 (29) . This plasmid was cotransfected with the resistance plasmid pKEX (33) (hygromycin resistance) in a second step into the stable cell lines.
Modulation of ADp-1 or AE2F-2 expression was induced by incubating the cells in medium in the presence (2 Ixg/ml) or absence of tetracycline. In addition, full-length DP-I clones (1-410 aa) and mock transfectants containing no insert in pUHD 10-3 were generated by the same protocol. Furthermore, using the expression plasmid pKEX, we selected HBL-100 clones, which expressed ADp-1 constitutively (ADp-lc).
Electrophoretic Mobility Shift Assay (EMSA). Preparation of nuclear extracts and EMSAs were performed as described (34, 35) . Briefly, 2.5 p~g of nuclear extract was incubated with 1 ~g ofpoly (deoxyinosine-deoxycytidine) (poly [dI-dC]) for 20 rain on ice and 32p-labeled double-stranded oligonucleotides containing a binding site for E2F/DP ( 5 ' -A T T T A A G T T T C G C G C C C T -TTCTCAA-3') and subsequently analyzed by native PAGE. pH]Thymidine Incorporation Assay. 5 • 104 cells/well were cultured in medium in 96-well round-bottom plates at 37~ for 72 h. The cells were pulsed with 1 p~Ci of [3H]Thymidine (Amersham, Braunschweig, Germany) after 3 d of culture, and DNA synthesis was measured during the last 16 h of culture. The cells were harvested onto glass filters, and the incorporated radioactivity was measured using a TopCount counter (Canberra Packard, Frankfurt, Germany).
Chloramphenicol Acetyl Transferase (CAT) Assay. CAT assays were performed using a reporter plasmid E2F4CAT containing the CAT gene under the control of an E2F-dependent promoter (36) . Transfection with 20 p~g of superhelical reporter plasmid DNA per 106 cells in 9-mm culture dishes was carried out by the calcium phosphate coprecipitation technique as described previously (37) . At 48 h after transfection, cellular proteins were extracted by a freeze-thaw procedure, and the CAT activity was determined as described previously (37) .
Immunocytology. Immunoperoxidase staining of HBL-100 cells was performed using the Vecta stain ABC kit (Vector Laboratories, Burlingame, CA), according to the manufacturer's protocol.
Anti-c-myc mAb was purchased from Dianova (Hamburg, Germany); anti-PCNA mouse mAb was purchased from Oncogene Science (Cambridge, MA). Polyclonal anti-Ki-67 rabbit serum was purchased from Dako (Hamburg, Germany).
Determination of Apoptotic Cells by Acridine Orange Staining.
Cells were cultured as described above. Apoptosis was induced by serum depletion. After induction ofapoptosis, cultures were seeded at 3 • 105 cells per 1-ml tissue culture well in RPMI 1640, stained with acridine orange (5 Ixg/ml), and observed by fluorescence microscopy. The number o f fragmented nuclei, which reliably indicates apoptosis, was determined.
DNA Fragmentation Assay.
For DNA fragmentation analysis, cell lysates were obtained by incubating a cell pellet containing 10 ~ cells in 20 ml oflysis buffer (10 mM EDTA, 50 mM Tris, pH 8, 0.5% sarcosyl, 0.5 mg/ml proteinase K) for 1 h at 50~ After addition of 5 ml of RNase (1 mg/ml) and another incubation for 1 h at 50~ lysates were electrophoresed on a 2% agarose gel containing ethidium bromide. The gel was run in a buffer conraining 26 M Na/HPO 4, 33 mM NaH2PO4, 10 mM EDTA; it was photographed under UV illumination.
Xenotransplantation of Cells into SCID Mice. HBL-100 cells (106)
were injected subcutaneously into C.B.-17 scid/scid mice. The mice were obtained from our own breeding colony and were kept in isolators under stringent conditions in the central animal laboratory of the Max Delbriick Center for Molecular Medicine. Microbiological controls were performed regularly by addition of sterile sentinel animals to the colony. Tumors were measured in millimeters in two dimensions, length (a) and width (b), using calipets. Tumor volume (V) was calculated according to V = ab2/2, where a is the longer of the two measurements. To repress ADP-1 expression in vivo, the drinking water was replaced with 2.5% sucrose containing 1.0 mg/ml tetracycline hydrochloride (Sigma Chemical Co., St. Louis, MO) as described previously (38) .
Results and Discussion
Truncated DP-1 and E2F-2 Constructs Block Endogenous E2F/DP Activity. T o downregnlate endogenous E 2 F / D P activity, we designed DP-1 and E2F-2 mutants (ADP-1 and AE2F-2) that may act in a dominant-negative m a n n e r to functionally inactivate endogenous E2F activities. Both constructs, ADP-1 and AE2F-2, contained D N A -b i n d i n g domains b u t were devoid o f the transactivation domain (23, (30) (31) (32) . By use of a tetracycline-controlled expression system, the constructs were expressed in H B L -1 0 0 cells (a n o n t u m o r i g e n i c p e r m a n e n t cell line) derived from n o n m alignant h u m a n breast epithelium. Withdrawal o f tetracycline led to the induction of ADP-1 or ~E 2 F -2 m R N A expression which was shown by R T -P C R (Fig. 1 a) . T h e upstream primer was chosen from the 5' transcribed region of the expression plasmid to discriminate b e t w e e n exogenous and endogenous ADP-1 or AE2F-2. W e m o n i t o r e d the induction of ADP-1 and AE2F-2 by EMSAs and found that both ADP-1 and AE2F-2 competed for D N A b i n d i n g with the endogenous E 2 F / D P -1 heterodimer (Fig. 1 b) . Tetracycline withdrawal led to complete disappearance o f the endogenous E 2 F / D P b i n d i n g complex, which was re- (a) Stable clones, which are under transcriptional control of a tetracycline (tet)-dependent transactivator, were generated, as described in Materials and Methods. HBL-100 clones transfected with either truncated DP-1 (ZIDP-1), truncated E2F-2 (AE2F-2), or full-length DP-1 (DP-I) were analyzed by RT-PCK. The upstream primer was chosen from the 5' transcribed region of the expression plasmid to discriminate between exogenous and endogenous DP-1. The resulting fragment lengths are indicated. Cells were cultured in the presence (+) or absence (-) of tetracycline. RNA was extracted 24 h after tetracycline withdrawal. Induction of ADP-1, AE2F-2, and DP-1 expression can be detected after tetracycline withdrawal, whereas in the presence of tetracycline, expression is completely repressed. 13-Actin and mock transfectants served as controls. (b) Nuclear E2F/DP-binding complexes of inducible and constitutive HBL-100 clones. The same clones as in a and one constitutive ADP-1 clone (ADP-lc) were analyzed by EMSA. Where indicated, a 50-M excess of unlabeled binding oligonucleotide was added to show specificity of DNA-binding complexes. Cells were cultured in the presence (+) or absence (-) of tetracycline. Nuclear protein was extracted 24 h after tetracycline withdrawal. Induction of ADP-1 or AE2F-2 expression leads to complete disappearance of the endogenous E2F/DP binding complex, which is replaced by a smaller complex. Full-length DP-1 and mock transfectants served as controls.
placed by a faster-migrating complex that most likely contained the truncated mutants. T o test whether truncated DP-1 or truncated E2F-2 inhibits E 2 F -d e p e n d e n t transcriptional activity, we transfected reporter genes u n d e r the control of an E 2 F -d e p e n d e n t p r o m o t e r into ADP-1 and AE2F-2 clones of HBL-100. As depicted in Fig. 2 a, strongly decreased C A T activity could be observed after induction of either ADP-1 or AE2F-2.
Using immunocytological staining, we were also able to show that induction of A D p l led to strong downregulation of endogenous c-myc (Fig. 2 b) , w h i c h contains E 2 F -b i n ding sites in its promoter and has been described as a target gene of E 2 F / D P (39). T h e same result was observed using the E2F-2 mutant (not shown). Expression of Ki-67, a marker indicating that the cycling state of cells, was n o t affected by the induction of ADp-1 (Fig. 2 b) . Thus, truncated D P -1 or E2F-2 blocked E 2 F / D P -d e p e n d e n t transcriptional activity, which was consistent with the complete disappearance of endogenous E 2 F 7 D P b i n d i n g complex in EMSAs (see Fig. 1 ). From these results, we conclude that our truncated constructs are dominant-negative mutants that are able to block E 2 F / D P . at the G1/S boundary and during S phase o f the cell cycle. E2F-mediated transcriptional activation includes genes that are important for S phase progression; therefore, E2F may be one o f the rate-limiting steps in cell proliferation. For this reason, we were interested to find out whether expression of the dominant-negative E2F/DP mutants would influence proliferation and D N A synthesis. Surprisingly, blocking o f E2F did not alter the proliferation rate or the D N A synthesis rate o f HBL-100 cells (Fig. 3) . These results are in contrast to the biological effect of similar dominant-negative E2F mutants described in quiescent 3T3 fibroblasts (40) . In these cells, a AE2F mutant blocked cell cycle progression induced by the adenovirus protein E1A. E I A acts via the E2F pathway by liberating E2F from multicomponent complexes that contain the product o f the retinoblastoma gene, pRb, and related proteins. In the fibroblasts, cell cycle progression is E2F-dependent and could therefore be blocked by E2F dominant-negative mutants. Although we can not exclude the possibility that unaffected cell cycle progression in HBL-100 cells expressing either ADP-1 or AE2F-2 could be due to incomplete suppression of endogenous E2F activity, we propose that cell cycle progression and transcription of important S phase genes could be driven in an E2F-independent manner. This hypothesis is supported by our observation that PCNA, an important cell cycle regulating S phase protein, which is another potential target gene o f E2F, was not affected by our dominant-negative mutants (not shown). Therefore, it seems that some (naturally occurring) E2F-responsive promoters can be downregulated (c-myc) by such mutants but others cannot be (PCNA).
Blocking of Endogenous E2F/DP Activity Does Not Alter the Proliferation Rate of HBL-IO0 Cells. E2F is thought to act
Blocking of Endogenous E2F/DP Activity Inhibits Induction of Apoptosis. Next we wanted to know whether blocking o f endogenous E2F alters sensitivity toward apoptosis. W e therefore induced apoptosis by serum depletion and asked whether the expression o f either ADP-1 or AE2F-2 would affect apoptosis. Our results show that after induction o f ADP-1 or AE2F-2, apoptosis could be blocked for 10 d (Fig. 4) . In contrast, in the presence of tetracychne, our Induction of ADP-1 or AE2F-2 expression in HBL-IO0 cells has no effect on the rate of DNA synthesis or cell proliferation. mock-transfected cell clones started to die via apoptosis after 1 d of serum starvation. Therefore, it appears that induction of apoptosis by growth factor depletion in cycling ceils was at least in part mediated by an E2F-dependent pathway. This concept is in accord with previous findings that in vivo overexpression of exogenous E2F-1 induced apoptosis in fibroblasts (25) (26) (27) (28) . It has been shown that constitutive c-myc expression causes apoptosis in serumstarved cells (11) . W e have shown that blocking of endogenous E2F led to downregulation of endogenous c-myc expression and inhibition of apoptosis. Therefore, one might speculate that E2F-dependent apoptosis could be regulated at least in part by transcription o f the c-myc gene. Our findings are strengthened by the fact that the retinoblastoma gene product, an important regulator o f E2F, also inhibits apoptosis (13) .
Thus, E 2 F / D P is a transcription factor involved in the regulation of two different biological processes and therefore provides another example of the close linkage between apoptosis and control of the cell cycle.
Blocking of Endogenous E2F/DP Activity in Normal Breast
Epithelial Cell Line HBL-I O0 Induces Tumor Growth in SCID Mice. W e recently provided evidence that dysregulation of apoptosis might be an important step in the pathogenesis o f breast cancer (9) . Therefore, we were interested in determining whether enhanced resistance to apoptosis o f ADP-1 or AE2F-2 expressing cells would induce tumorgenicity. We transplanted ADP-1 and mock-transfected HBL-100 cells into SCID mice. To suppress ADP-1 or AE2F-2 expression in vivo, tetracycline was added to the animals' drinking water. As depicted in Fig. 5 , tumor growth was observed only in animals that carried either ADP-1-or AE2F-2-expressing cells and obtained no tetracycline from their drinking water. No tumor growth was observed in animals that were challenged with HBL-100 cells but that did not express truncated mutants. Therefore, we conclude that blocking of endogenous E2F activity can induce tumor growth in SCID mice and that this induction is most likely due to an enhanced resistance to apoptosis. It appears that, in cells proliferating in an E2F-independent manner, E2F has a potential tumor-suppressive function. Recently, it has been reported that induction of apoptosis in E2F-overexpressing cells depends on the expression of p53 (27, 28) .
Therefore, it will be interesting to look for loss of function mutations of the E2F/DP family, particularly in p53-expressing tumors. Thus, we provide further evidence that dysregulation of apoptosis is an important step in tumorigenesis.
In conclusion, we found that downregulation of endogenous E2F/DP activity did not affect the proliferation rate of the breast epithelial cell line HBL-100 but led to downregulation of c-myc expression, enhanced resistance toward apoptosis, and induction of tumorigenic growth in SCID mice. Therefore, we propose the following three hypotheses. First, cell cycle progression can be driven in an E2F independent manner. Second, endogenous E2F is involved in the regulation of apoptosis (possibly via transcriptional regulation of c-myc expression). Third, under certain circumstances, E2F has a potential tumor-suppressive function. 
